Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isavuconazole PK and TDM in Children
NCT06440915Recruiting
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of isavuconazole in invasive aspergillosis (IA) and mucormycosis. Primary endpoint: Plasma concentrations of isavuconazole. Started Jun 2024; status: recruiting.
02
Drugs
isavuconazole
03
Conditions
invasive aspergillosis (IA)mucormycosis
Beyond the preview
Go deeper on NCT06440915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06440915.